Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

April 24, 2024

https://www.globenewswire.com/news-release/2024/04/24/2868751/0/en/Caribou-Biosciences-to-Present-Initial-Dose-Expansion-Data-from-CB-010-ANTLER-Phase-1-Trial-in-r-r-B-NHL-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html

BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.